JAC Advance Access originally published online on December 23, 2004
Journal of Antimicrobial Chemotherapy 2005 55(2):194-199; doi:10.1093/jac/dkh548
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
JAC vol.55 no.2 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved
In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002–2003
1 Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Ctra Majadahonda-Pozuelo Km 2, 28220 Majadahonda, Madrid; 2 Infectious Diseases Division, Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona; 4 Microbiology Department, Hospital Universitari Vall d'Hebron, Barcelona; 5 Microbiology Department, Hospital Clínic-IDIBAPS, Barcelona; 6 Infectious Diseases Division, Hospital Clínic-IDIBAPS, Barcelona; 7 Microbiology Department, Hospital de la Santa Creu i Sant Pau, Barcelona; 8 Microbiology Department, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona; 9 Microbiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona; 10 Hospital del Mar, Barcelona, Spain; 3 Mycotic Diseases Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Diseases Control and Prevention, Atlanta, GA, USA
* Corresponding author. Tel: +34-91-5097961; Fax: +34-91-5097966; Email: mcuenca-estrella{at}isciii.es
Objectives:
The antifungal drug susceptibilities of 351 isolates of Candida species, obtained through active laboratory-based surveillance in the period January 2002–December 2003, were determined (Candida albicans 51%, Candida parapsilosis 23%, Candida tropicalis 10%, Candida glabrata 9%, Candida krusei 4%).
Methods:
The MICs of amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and caspofungin were established by means of the broth microdilution reference procedure of the European Committee on Antibiotic Susceptibility Testing.
Results and conclusions:
Amphotericin B and flucytosine were active in vitro against all strains. A total of 24 isolates (6.8%) showed decreased susceptibility to fluconazole (MIC 
16 mg/L) and 43 (12.3%) showed decreased susceptibility to itraconazole (MIC 0.25 mg/L). Voriconazole and caspofungin were active in vitro against the majority of isolates, even those that were resistant to fluconazole.
Keywords: fluconazole resistance , caspofungin , voriconazole , EUCAST
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Desnos-Ollivier, S. Bretagne, D. Raoux, D. Hoinard, F. Dromer, and E. Dannaoui Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3092 - 3098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Desnos-Ollivier, F. Dromer, and E. Dannaoui Detection of Caspofungin Resistance in Candida spp. by Etest J. Clin. Microbiol., July 1, 2008; 46(7): 2389 - 2392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gomez-Lopez, A. Alastruey-Izquierdo, D. Rodriguez, B. Almirante, A. Pahissa, J. L. Rodriguez-Tudela, M. Cuenca-Estrella, and and the Barcelona Candidemia Project Study Group Prevalence and Susceptibility Profile of Candida metapsilosis and Candida orthopsilosis: Results from Population-Based Surveillance of Candidemia in Spain Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1506 - 1509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Dannaoui, O. Lortholary, D. Raoux, M. E. Bougnoux, G. Galeazzi, C. Lawrence, D. Moissenet, I. Poilane, D. Hoinard, F. Dromer, et al. Comparative In Vitro Activities of Caspofungin and Micafungin, Determined Using the Method of the European Committee on Antimicrobial Susceptibility Testing, against Yeast Isolates Obtained in France in 2005-2006 Antimicrob. Agents Chemother., February 1, 2008; 52(2): 778 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Lortholary, E. Dannaoui, D. Raoux, D. Hoinard, A. Datry, A. Paugam, J.-L. Poirot, C. Lacroix, F. Dromer, and the YEASTS Group In Vitro Susceptibility to Posaconazole of 1,903 Yeast Isolates Recovered in France from 2003 to 2006 and Tested by the Method of the European Committee on Antimicrobial Susceptibility Testing Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3378 - 3380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B.-v. Zepelin, L. Kunz, R. Ruchel, U. Reichard, M. Weig, and U. Gross Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005 J. Antimicrob. Chemother., August 1, 2007; 60(2): 424 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pfaller and D. J. Diekema Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem Clin. Microbiol. Rev., January 1, 2007; 20(1): 133 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Girmenia, G. Pizzarelli, F. Cristini, F. Barchiesi, E. Spreghini, G. Scalise, and P. Martino Candida guilliermondii Fungemia in Patients with Hematologic Malignancies. J. Clin. Microbiol., July 1, 2006; 44(7): 2458 - 2464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Almirante, D. Rodriguez, M. Cuenca-Estrella, M. Almela, F. Sanchez, J. Ayats, C. Alonso-Tarres, J. L. Rodriguez-Tudela, A. Pahissa, and the Barcelona Candidemia Project Study Group Epidemiology, Risk Factors, and Prognosis of Candida parapsilosis Bloodstream Infections: Case-Control Population-Based Surveillance Study of Patients in Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol., May 1, 2006; 44(5): 1681 - 1685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, D. J. Diekema, and D. J. Sheehan Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing Clin. Microbiol. Rev., April 1, 2006; 19(2): 435 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Magill, C. Shields, C. L. Sears, M. Choti, and W. G. Merz Triazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy J. Clin. Microbiol., February 1, 2006; 44(2): 529 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Marine, C. Serena, B. Fernandez-Torres, F. J. Pastor, and J. Guarro Activities of Flucytosine, Fluconazole, Amphotericin B, and Micafungin in a Murine Model of Disseminated Infection by Candida glabrata Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4757 - 4759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Laupland, D. B. Gregson, D. L. Church, T. Ross, and S. Elsayed Invasive Candida species infections: a 5 year population-based assessment J. Antimicrob. Chemother., September 1, 2005; 56(3): 532 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema In Vitro Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species to Itraconazole: Global Survey of 9,359 Isolates Tested by Clinical and Laboratory Standards Institute Broth Microdilution Methods J. Clin. Microbiol., August 1, 2005; 43(8): 3807 - 3810. [Abstract] [Full Text] [PDF]
|
|